December 29, 2023 Regulatory Kommuniké från Promore Pharma AB:s extra bolagsstämma den 29 december 2023
December 29, 2023 Regulatory Report from the Extraordinary General Meeting of Promore Pharma AB held on 29 December 2023
December 21, 2023 Regulatory Promore Pharma AB (publ) has received approval for continued trading on Nasdaq First North Growth Market and publishes company description
December 21, 2023 Regulatory Promore Pharma AB (publ) har erhållit godkännande för fortsatt handel på Nasdaq First North Growth Market och offentliggör bolagsbeskrivning
December 8, 2023 Regulatory Update on reverse acquisition – PMD completes private placement and major shareholder receives exemption from mandatory bid requirements
December 8, 2023 Regulatory Uppdatering om det omvända förvärvet – PMD slutför riktad nyemission och större aktieägare erhåller undantag från budplikt
November 29, 2023 Regulatory Correction: NOTICE OF EXTRAORDINARY GENERAL MEETING IN PROMORE PHARMA AB (PUBL)
November 29, 2023 Regulatory Promore Pharma AB avser att genomföra ett omvänt förvärv av PMD Device Solutions AB
November 29, 2023 Regulatory Promore Pharma AB intends to carry out a reverse acquisition of PMD Device Solutions AB
October 5, 2023 Regulatory Report from the Extraordinary General Meeting of Promore Pharma AB held on 5 October 2023
June 27, 2023 Regulatory Report from the Annual General Meeting of Promore Pharma AB held on 27 June 2023
June 22, 2023 Regulatory Promore Pharma minskar kostnader och undersöker förutsättningar för ett omvänt förvärv
June 22, 2023 Regulatory Promore Pharma reduces costs and explores the conditions for a reverse acquisition
April 20, 2023 Regulatory Invitation to a presentation of the results from Promore Pharma’s clinical trial PHSU05
April 20, 2023 Regulatory Promore Pharma rapporterar utfall från klinisk fas II-studie med ensereptide
April 20, 2023 Regulatory Promore Pharma reports outcome from clinical Phase II study with ensereptide
February 27, 2023 Regulatory Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Fourth Quarter 2022
February 27, 2023 Regulatory Promore Pharma når milstolpen Clean File i sin kliniska fas II-studie med ensereptide
February 27, 2023 Regulatory Promore Pharma reaches the Clean File milestone in its phase II clinical trial with ensereptide
November 24, 2022 Regulatory Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2022
November 23, 2022 Regulatory Nomination Committee Appointed for the Annual General Meeting 2023 in Promore Pharma
November 1, 2022 Regulatory Promore Pharma provides an update on the Phase II clinical trial with ensereptide
August 23, 2022 Regulatory Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Second Quarter 2022
August 23, 2022 Regulatory Inbjudan till telefonkonferens om Promore Pharmas rapport för det andra kvartalet 2022
August 10, 2022 Regulatory Promore Pharma beviljas patent i Europa avseende behandling av kroniska sår
June 13, 2022 Regulatory The last clinic visit conducted in Promore Pharma’s phase II study of ensereptide
June 13, 2022 Regulatory Sista klinikbesöket genomfört i Promore Pharmas fas II-studie av ensereptide
May 17, 2022 Regulatory Report from the Annual General Meeting of Promore Pharma AB held on 17 May 2022
May 13, 2022 Regulatory Inbjudan till telefonkonferens om Promore Pharmas rapport för det första kvartalet 2022
May 13, 2022 Regulatory Invitation to Conference Call regarding Promore Pharma’s Interim Report for the First Quarter 2022
March 17, 2022 Regulatory Promore Pharma has reached recruitment goal in clinical trial of ensereptide
February 16, 2022 Regulatory Första patient rekryterad till Promore Pharmas kliniska prövning rörande ärrbildning enligt plan
February 16, 2022 Regulatory First patient recruited to Promore Pharma’s clinical trial regarding scarring according to plan
February 9, 2022 Regulatory Inbjudan till telefonkonferens med anledning av Promore Pharmas Bokslutskommuniké 2021
February 9, 2022 Regulatory Invitation to Conference Call regarding Promore Pharma’s Year-end Report 2021
November 19, 2021 Regulatory Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2021
November 19, 2021 Regulatory Inbjudan till telefonkonferens med anledning av Promore Pharmas rapport för det tredje kvartalet 2021
November 16, 2021 Regulatory Nomination Committee Appointed for the Annual General Meeting 2022 in Promore Pharma
November 9, 2021 Regulatory Promore Pharma erhåller tillstånd för att starta fas II klinisk prövning avseende ärrprevension
November 9, 2021 Regulatory Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention
October 25, 2021 Regulatory Promore Pharma meddelar att vetenskaplig artikel publicerats om kliniska studieresultat med ropocamptide för venösa bensår
October 25, 2021 Regulatory Promore Pharma announces that scientific article has been published on clinical study results with ropocamptide for venous leg ulcers
September 13, 2021 Regulatory Promore Pharma receives delivery of hyaluronic acid from Italian manufacturer Fidia
July 20, 2021 Regulatory The rights issue is registered and the trading in Paid Subscription Shares ceases
May 27, 2021 Regulatory Promore Pharma informerar om sista dag för handel för att erhålla teckningsrätter
May 27, 2021 Regulatory Promore Pharma informs about the last day of trading to receive subscription rights
May 27, 2021 Regulatory Report from an extra General Meeting of Promore Pharma AB held on 27 May 2021
May 27, 2021 Regulatory Report from the Annual General Meeting of Promore Pharma AB held on 27 May 2021
May 26, 2021 Regulatory Promore Pharma participates in “Småbolagsdagarna 2021”, an event organized by Aktiespararna
May 7, 2021 Regulatory Promore Pharma AB intends to carry out a fully secured rights issue in order to implement the new strategy
May 7, 2021 Regulatory Promore Pharma genomför en fullt garanterad företrädesemission i syfte att genomföra den nya strategin
April 28, 2021 Regulatory Promore Pharma tecknar avtal om produktion av hyaluronsyra med italienska tillverkaren Fidia
April 28, 2021 Regulatory Promore Pharma signs agreement on production of hyaluronic acid with Italian manufacturer Fidia
February 16, 2021 Regulatory Inbjudan till presentation av Promore Pharmas bokslutskommuniké för 2020
November 20, 2020 Regulatory Inbjudan till telefonkonferens med anledning av Promore Pharmas rapport för det tredje kvartalet 2020
November 20, 2020 Regulatory Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2020
November 19, 2020 Regulatory Promore Pharma meddelar positiva resultat från fas IIb-studie av ropocamptide vid behandling av venösa bensår
November 19, 2020 Regulatory Promore Pharma announces positive results from Phase IIb study of ropocamptide in the treatment of venous leg ulcers
October 27, 2020 Regulatory Nomination Committee Appointed for the Annual General Meeting 2021 in Promore Pharma
August 19, 2020 Regulatory Inbjudan till presentation av Promore Pharmas delårsrapport för det andra kvartalet 2020
August 19, 2020 Regulatory Invitation to Presentation of Promore Pharma’s Interim Report for the Second Quarter 2020
May 26, 2020 Regulatory Report from the Annual General Meeting of Promore Pharma AB held on 26 May 2020
May 25, 2020 Regulatory Invitation to Conference Call regarding Promore Pharma’s Interim Report for the First Quarter 2020
May 25, 2020 Regulatory Inbjudan till telefonkonferens med anledning av Promore Pharmas rapport för det första kvartalet 2020
March 24, 2020 Regulatory Promore Pharma nådde målsättningen i antalet behandlade patienter i den kliniska fas IIb-studien HEAL LL-37
March 24, 2020 Regulatory Promore Pharma reached the targeted number of patients completing treatment in the HEAL LL-37 Phase IIb clinical trial
February 13, 2020 Regulatory Inbjudan till presentation av Promore Pharmas bokslutskommuniké för 2019
December 10, 2019 Regulatory Promore Pharma has finalized recruitment of patients in HEAL LL-37 early
November 22, 2019 Regulatory Promore Pharma offentliggör tilläggsprospekt avseende pågående föresträdesemission
November 22, 2019 Regulatory Promore Pharma publishes supplementary prospectus in connection with the ongoing rights issue
October 22, 2019 Regulatory Report from the Extraordinary Shareholders’ Meeting of Promore Pharma AB held on 22 October 2019
October 17, 2019 Regulatory Nomination Committee Appointed for the Annual General Meeting 2020 in Promore Pharma
October 4, 2019 Regulatory Promore Pharma genomför en företrädesemission om cirka 75 MSEK, garanterad upp till 80 procent, och tidigarelägger kvartalsrapport
October 4, 2019 Regulatory Promore Pharma Promore Pharma carries out a rights issue of approximately SEK 75 million, underwritten up to 80 percent, and intends to publish its interim report early
August 23, 2019 Regulatory Inbjudan till presentation av Promore Pharmas delårsrapport för det andra kvartalet 2019
August 23, 2019 Regulatory Invitation to Presentation of Promore Pharma’s Interim report for the second quarter 2019
May 21, 2019 Regulatory Report from the Annual General Meeting of Promore Pharma AB held on 21 May 2019
May 15, 2019 Regulatory Invitation to Presentation of Promore Pharma’s Interim report for the first quarter 2019
May 15, 2019 Regulatory Inbjudan till presentation av Promore Pharmas delårsrapport för det första kvartalet 2019
February 1, 2019 Regulatory Promore Pharma modifies its Phase III trial of PXL01 and expands the number of clinics in the study
February 1, 2019 Regulatory Promore Pharma modifierar sin fas III-prövning av PXL01 och utökar antalet kliniker i studien
November 19, 2018 Regulatory Promore Pharma receives approval for Phase III study with PXL01 in India
November 19, 2018 Regulatory Promore Pharma erhåller godkännande för fas III-studie med PXL01 i Indien
November 9, 2018 Regulatory Nomination Committee Appointed for the Annual General Meeting 2019 in Promore Pharma
September 6, 2018 Regulatory Promore Pharma has conducted Investigator Meeting for HEAL LL-37 in Poland
September 3, 2018 Regulatory Promore Pharma planerar att bredda den terapeutiska peptiden PXL01 att också inkludera ärrbildning på hud
September 3, 2018 Regulatory Promore Pharma Plans to Expand Indications of Therapeutic Peptide PXL01 in the Field of Dermal Scarring
August 14, 2018 Regulatory Invitation to Presentation of Promore Pharma’s Interim report for the second quarter 2018
August 14, 2018 Regulatory Inbjudan till presentation av Promore Pharmas rapport för andra kvartalet 2018
May 16, 2018 Regulatory Report from the Annual General Meeting of Promore Pharma AB held on 16 May 2018
May 9, 2018 Regulatory Invitation to Presentation of Promore Pharma’s Interim report for the first quarter 2018
May 9, 2018 Regulatory Inbjudan till presentation av Promore Pharmas rapport för första kvartalet 2018
May 7, 2018 Regulatory Promore Pharma Out-licenses PXL01 for Spinal Surgery to PharmaResearch Products Ltd
May 7, 2018 Regulatory Promore Pharma utlicensierar PXL01 för ryggradskirurgi till PharmaResearch Products Ltd
April 24, 2018 Regulatory Promore Pharma har lämnat underlag avseende investeraravdrag till Skatteverket
April 4, 2018 Regulatory Two new smart-phone based imaging products have been adopted by Promore Pharma AB
November 14, 2017 Regulatory Promore Pharma Signs Out-licensing Agreement with Transdermal Therapeutic Technologies for its Peptide DPK-060
November 14, 2017 Regulatory Promore Pharma tecknar utlicensieringsavtal för DPK-060 med Transdermal Therapeutic Technologies
October 30, 2017 Regulatory Promore Pharma slutför ett omfattande europeiskt samarbete avseende DPK-060
October 30, 2017 Regulatory Promore Pharma Completes Extensive European Collaboration Regarding DPK-060
September 12, 2017 Regulatory Promore Pharma presents at the symposium for hard-to-heal wounds in connection with Nordic Life Science Days
September 12, 2017 Regulatory Promore Pharma presenterar på symposium för svårläkta sår i anslutning till Nordic Life Science Days
June 30, 2017 Non Regulatory Promore Pharma väntar godkännade för listning på Nasdaq First North under nästa vecka
June 26, 2017 Non Regulatory New share issue in Promore Pharma raises 76 MSEK ahead of listing on Nasdaq First North
June 7, 2017 Non Regulatory Promore Pharma Carries Out a Share Issue Prior to Listing on Nasdaq First North
April 26, 2017 Regulatory Promore Pharma utser Marianne Dicander Alexandersson till ny styrelseledamot och meddelar planer för notering på Nasdaq First North
April 26, 2017 Regulatory Promore Pharma AB elects Marianne Dicander Alexandersson as New Board Member and outlines plans for IPO
December 21, 2016 Regulatory Promore Pharma and Cellastra Inc. Announce Phase III Clinical Collaboration to Develop Therapeutic Peptide PXL01 for the US Market
July 8, 2016 Regulatory Promore Pharma Announces a Strategic Collaboration with Technomark Life Sciences
May 31, 2016 Regulatory Promore Pharma Obtains Positive Feedback in Dialogue with The Medical Products Agency of Sweden
March 8, 2016 Regulatory Lipopeptide AB Announces a Strategic Collaboration with Pharmaresearch Products LTD
October 10, 2013 Regulatory Pergamum Announces Final Data from Phase I/II Study in Patients with Chronic Leg Ulcers
June 27, 2013 Regulatory Pergamum Reports Positive Follow-Up Data from a Phase II Clinical Trial of PXL01 for Prevention of Post-Surgical Adhesions
February 8, 2013 Regulatory Pergamum Announces a Strategic Collaboration with Cadila Pharmaceuticals Ltd.